Takeda Pharmaceutical is seeking approval from the Japanese Ministry of Health Labour and Welfare for its Leuplin six month depot (leuprorelin acetate) to treat prostate and premenopausal breast cancer.

A new drug application (NDA) to this effect has been submitted by the company to the Japanese ministry.

Leuplin is an LH-RH agonist, which consistently stimulates the pituitary gland to suppress the production of male/female hormone.

"Studies assessed the safety, efficacy, pharmacokinetics and hormone dynamics."

The company submitted the application based on the results of two clinical Phase III studies in patients with prostate cancer and those with premenopausal breast cancer through multicentre, randomised, open label and comparative studies.

Studies assessed the safety, efficacy, pharmacokinetics and hormone dynamics, according to the company.

Initially, Takeda launched Leuplin as a once-daily administration by injection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following use of several applications in drug formulation technology, the company was able to develop Leuplin into a sustained-release microcapsule depot formulation, enabling to maintain stable blood concentration levels over a long period of time.

Currently, one month and three month formulations have received approval and are marketed in Japan.

The six month depot allows the treatment with one administration at every 24 weeks, are is now available in markets such as the US, Europe and a few countries in Asia.

Takeda said that the new treatment for both prostate cancer and premenopausal breast cancer will be delivered through its drug delivery system.